BACKGROUND: The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of paclitaxel administered at a maximum dose density for patients with chemotherapy-naïve, advanced-stage non-small cell lung carcinoma (NSCLC). METHODS: Patients with Stage IIIB/IV or recurrent NSCLC, a performance status (PS) score of 0-1, and no history of chemotherapy exposure were eligible. Paclitaxel, 150 mg/m(2), was administered over 3 hours during Weeks 1-6 of an 8-week cycle. Doses were modified for ANC < 1500/microL or for >or= Grade 2 neuropathy on the day of therapy. Treatment continued until toxicity or disease progression. Pharmacokinetics were assessed at Weeks 1, 3, and 5 of Cycle 1. RESULTS: Thirty-eight patients (median age, 64 years; range, 31-81 years) were treated. There were 21 males (PS = 0 for 17). Eleven patients had received previous radiation, 2 had brain metastases, 25 had adenocarcinoma, 23 had Stage IV disease, 6 had StageIIIB disease, and 9 had recurrent disease. Grade 3-4 granulocytopenia occurred in 39% of patients. There were no deaths due to toxicity. Grade 2 or 3 neuropathy occurred in 29% and 24% of patients, respectively. Ten (27%) patients had Grade 3 hyperglycemia (glucose concentration > 250 mg/dL). There were 16 partial responses (42%; 95% confidence interval [CI], 26-59%). The median survival period was 12.3 months (95% CI, 7.9-19.6%), and the 1-year and 2-year survival rates were 52% (95% CI, 39-71%) and 26% (95% CI, 15-45%), respectively. Paclitaxel pharmacokinetics were consistent with published values and clearance was not induced. Older age and hyperglycemia were associated with greater neurotoxicity. CONCLUSIONS: Paclitaxel at 150 mg/m(2) per week x 6 every 8 weeks can be administered safely in the cooperative group setting. These Phase II data are comparable to those associated with combination therapy. The weekly dose-dense schedule may be more active than conventional schedules. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11375
BACKGROUND: The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of paclitaxel administered at a maximum dose density for patients with chemotherapy-naïve, advanced-stage non-small cell lung carcinoma (NSCLC). METHODS:Patients with Stage IIIB/IV or recurrent NSCLC, a performance status (PS) score of 0-1, and no history of chemotherapy exposure were eligible. Paclitaxel, 150 mg/m(2), was administered over 3 hours during Weeks 1-6 of an 8-week cycle. Doses were modified for ANC < 1500/microL or for >or= Grade 2 neuropathy on the day of therapy. Treatment continued until toxicity or disease progression. Pharmacokinetics were assessed at Weeks 1, 3, and 5 of Cycle 1. RESULTS: Thirty-eight patients (median age, 64 years; range, 31-81 years) were treated. There were 21 males (PS = 0 for 17). Eleven patients had received previous radiation, 2 had brain metastases, 25 had adenocarcinoma, 23 had Stage IV disease, 6 had StageIIIB disease, and 9 had recurrent disease. Grade 3-4 granulocytopenia occurred in 39% of patients. There were no deaths due to toxicity. Grade 2 or 3 neuropathy occurred in 29% and 24% of patients, respectively. Ten (27%) patients had Grade 3 hyperglycemia (glucose concentration > 250 mg/dL). There were 16 partial responses (42%; 95% confidence interval [CI], 26-59%). The median survival period was 12.3 months (95% CI, 7.9-19.6%), and the 1-year and 2-year survival rates were 52% (95% CI, 39-71%) and 26% (95% CI, 15-45%), respectively. Paclitaxel pharmacokinetics were consistent with published values and clearance was not induced. Older age and hyperglycemia were associated with greater neurotoxicity. CONCLUSIONS:Paclitaxel at 150 mg/m(2) per week x 6 every 8 weeks can be administered safely in the cooperative group setting. These Phase II data are comparable to those associated with combination therapy. The weekly dose-dense schedule may be more active than conventional schedules. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11375
Authors: D L Hertz; S Roy; A A Motsinger-Reif; A Drobish; L S Clark; H L McLeod; L A Carey; E C Dees Journal: Ann Oncol Date: 2013-02-14 Impact factor: 32.976
Authors: M C Pietanza; Matthew D Hellmann; John J Fiore; Stephanie Smith-Marrone; Ethan M Basch; Lawrence H Schwartz; Michelle S Ginsberg; Marwan Shouery; Samantha K Newman; Mary Shaw; Lauren J Rogak; Alex E Lash; Patrick Hilden; Mark G Kris Journal: J Thorac Oncol Date: 2016-03-08 Impact factor: 15.609
Authors: Patricia M M B Soetekouw; Johanna N H Timmer-Bonte; Miep A van der Drift; Frank van Leeuwen; Michiel Wagenaar; Lya van Die; Jan Bussink; Vivianne C G Tjan-Heijnen Journal: Int J Clin Oncol Date: 2012-09-27 Impact factor: 3.402
Authors: Bryan P Schneider; Fengmin Zhao; Molin Wang; Vered Stearns; Silvana Martino; Vicky Jones; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson; Joseph A Sparano Journal: J Clin Oncol Date: 2012-07-30 Impact factor: 44.544
Authors: Perran F Yumuk; Nazim S Turhal; Mahmut Gumus; Nilgun F Hatabay; Orhan Turken; Alper Ozkan; Taflan Salepci; Mehmet Aliustaoglu; Rengin Ahiskali Journal: BMC Cancer Date: 2005-01-25 Impact factor: 4.430
Authors: Daniel L Hertz; Kouros Owzar; Sherrie Lessans; Claudia Wing; Chen Jiang; William Kevin Kelly; Jai Patel; Susan Halabi; Yoichi Furukawa; Heather E Wheeler; Alexander B Sibley; Cameron Lassiter; Lois Weisman; Dorothy Watson; Stefanie D Krens; Flora Mulkey; Cynthia L Renn; Eric J Small; Phillip G Febbo; Ivo Shterev; Deanna L Kroetz; Paula N Friedman; John F Mahoney; Michael A Carducci; Michael J Kelley; Yusuke Nakamura; Michiaki Kubo; Susan G Dorsey; M Eileen Dolan; Michael J Morris; Mark J Ratain; Howard L McLeod Journal: Clin Cancer Res Date: 2016-05-03 Impact factor: 12.531